Forbes September 16, 2021
Russell Flannery

Prenetics Group, a Hong Kong-based genomic and diagnostic testing firm, and Artisan Acquisition, a Nasdaq-listed SPAC founded by businessman Adrian Cheng, on Wednesday announced a merger agreement that would value Prenetics at $1.2 billion.

The transaction would make Prenetics the first unicorn from Hong Kong to be publicly listed in any market, according to a Prenetics press release.

Prenetics, whose investors include Alibaba Group, will receive up to $459 million in cash, including up to $339 million of cash currently held in Artisan’s trust account, and $120 million through purchase agreements from Aspex, PAG, Lippo, Dragonstone, Xen Capital and others, along...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Former Bristol Myers CEO tapped as Novartis’ next board chair
The Power of Drug Discovery with Philip Tagari
Novartis raises forecasts as top drug sales beat Wall Street estimates
Pharma Pulse 4/23/24: Drug Discount Programs Poised to Change with New Tech, SpecialtyRx Savings Navigator to Enhance Affordability & more
AI Ushers in HPC Revival Says TACC’s Dan Stanzione

Share This Article